| Literature DB >> 35456862 |
Alessandra Alessiani1, Elisa Goffredo1, Maria Mancini1, Gilda Occhiochiuso1, Simona Faleo1, Antonella Didonna1, Rita Fischetto2, Federica Suglia3, Danila De Vito3, Antonella Stallone1, Luigi D'Attoli1, Adelia Donatiello1.
Abstract
Salmonella enterica is one of the most common causes of foodborne infection in the world, and the most common one in Italy. Italy collaborates with the other EU member states to survey the antimicrobial resistance of Salmonella on a large scale. This study on the situation in Apulia and Basilicata provides a more focused point of view on the territory, and anticipates the data reported in future Italian reports. Antimicrobial resistance was detected using the MIC detection method, with EUVSEC® plates, on the strains collected between 2017 and 2021. The results of serotyping showed that Salmonella Infantis is the serovar that has increased the most over time in veterinary samples, while Salmonella Tyhimurium and its monophasic variant are the most isolated in human samples. The results of the antimicrobial resistance study comply with European data, showing high resistance to quinolones, tetracyclines, ampicillin and trimethoprim, and low resistance to colistin and cephems. The significant exception was that all strains were resistant to sulphametoxazole. The presence of MDRs, which was 85% in veterinary and 77.4% in human strains, often included critically important antibiotics, which is a sign that more study and action is needed to manage the use of antibiotics.Entities:
Keywords: Italy; MDR; S. Derby; S. Infantis; S. Kentucky; S. Typhimurium; Salmonella; antimicrobial resistance; monophasic variant of Typhimurium
Year: 2022 PMID: 35456862 PMCID: PMC9031535 DOI: 10.3390/microorganisms10040812
Source DB: PubMed Journal: Microorganisms ISSN: 2076-2607
Figure 1Distribution of S. Infantis, MVST, S. Typhimurium, S. Kentucky, S. Derby and S. Enteritidis per year. FA strains.
Figure 2Distribution of S. Infantis, MVST, S. Typhimurium, S. Kentucky, S. Derby and S. Enteritidis per year. H strains.
Resistance percentage of the total strains to single antimicrobial agents. In bold are the highest priority critically important antimicrobials.
| Antimicrobial Agents | Human-Resistant Strains/TOT | Food–Animal-Resistant Strains/TOT |
|---|---|---|
| Sulfamethoxazole (SUL) | 100.0% | 100.0% |
|
|
|
|
|
|
|
|
| Tetracycline (TET) | 50.7% | 60.7% |
| Trimethoprim (TRI) | 6.2% | 42.7% |
| Ampicillin (AMP) | 57.5% | 41.3% |
|
|
|
|
|
|
|
|
| Tigecycline (TGC) | 2.7% | 7.8% |
|
|
|
|
| Chloramphenicol (CLO) | 9.6% | 6.3% |
| Amikacin (AMI) | 3.4% | 4.4% |
|
|
|
|
| Gentamicin (GEN) | 0.0% | 1.5% |
| Meropenem (MERO) | 0.0% | 0.0% |
Resistance to single antimicrobial agents for the serotypes of FA strains. In bold are the highest priority critically important antimicrobials.
| Antimicrobial Agents | VMST | |||||
|---|---|---|---|---|---|---|
| Ampicillin | 44.0% | 46.2% | 40.0% | 14.3% | 63.0% | 42.3% |
| Meropenem | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
|
| 69.0% | 76.9% | 80.0% | 77.1% | 18.5% | 38.5% |
| Azithromycin | 9.0% | 0.0% | 0.0% | 5.7% | 3.7% | 11.5% |
| Amikacin | 5.0% | 15.4% | 0.0% | 2.9% | 3.7% | 0.0% |
| Gentamicin | 0.0% | 7.7% | 0.0% | 0.0% | 7.4% | 0.0% |
| Tigecycline | 11.0% | 7.7% | 0.0% | 2.9% | 11.1% | 0.0% |
|
| 19.0% | 30.8% | 20.0% | 5.7% | 3.7% | 7.7% |
|
| 23.0% | 30.8% | 40.0% | 11.4% | 0.0% | 11.5% |
| Chloramphenicol | 5.0% | 0.0% | 0.0% | 2.9% | 11.1% | 15.4% |
|
| 2.0% | 7.7% | 0.0% | 2.9% | 0.0% | 7.7% |
|
| 70.0% | 69.23% | 80.0% | 85.7% | 18.5% | 50.0% |
| Tetracycline | 73.0% | 53.9% | 60.0% | 34.3% | 70.4% | 42.3% |
| Trimethoprim | 55.0% | 61.5% | 60.0% | 25.7% | 29.6% | 19.2% |
| Sulfamethoxazole | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
Resistance to single antimicrobial agents in the serotypes of H strains. In bold are the highest priority critically important antimicrobials.
| Antimicrobial Agents | MV | |||||
|---|---|---|---|---|---|---|
| Ampicillin | 85.7% | 33.3% | 3.7% | 0.0% | 63.6% | 75.0% |
| Meropenem | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
|
| 85.7% | 16.7% | 0.0% | 0.0% | 6.1% | 5.6% |
|
| 85.7% | 66.7% | 14.8% | 0.0% | 42.4% | 34.7% |
| Amikacin | 14.3% | 16.7% | 3.7% | 0.0% | 3.0% | 1.4% |
| Gentamicin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Tigecycline | 28.6% | 0.0% | 3.7% | 0.0% | 0.0% | 1.4% |
|
| 57.1% | 16.7% | 0.0% | 0.0% | 0.0% | 0.0% |
|
| 57.1% | 16.7% | 0.0% | 0.0% | 0.0% | 1.4% |
| Chloramphenicol | 14.3% | 16.7% | 7.4% | 0.0% | 6.1% | 11.1% |
|
| 14.3% | 0.0% | 7.4% | 0.0% | 0.0% | 1.4% |
|
| 71.4% | 0.0% | 7.4% | 0.0% | 9.1% | 2.8% |
| Tetracycline | 71.4% | 33.3% | 3.7% | 0.0% | 57.6% | 65.3% |
| Trimethoprim | 85.7% | 0.0% | 0.0% | 0.0% | 3.0% | 2.8% |
| Sulfamethoxazole | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |